The number of pets has been increasing year by year. Starting in 2020, the number of pets in Taiwan for the first time surpassed the number of children under 15, with approximately one pet for every 3-4 households. This indicates the rapid growth of the "pet economy."
As pets are increasingly considered family members, owners' growing concern for their pets' health has led to a significant increase in related medical expenditures. As a result, regenerative medicine technology has become a focal point for the industry, especially the application of exosomes. Past research has shown that exosomes have the properties of promoting cell regeneration, alleviating inflammation, and repairing tissues. They have been widely applied in areas such as pet arthritis, trauma and tissue repair, eye diseases, and immune regulation, and have shown positive treatment outcomes, providing new medical options for pets.
GWOXI Enters the Pet Regenerative Medicine Market
Leveraging its solid foundation in the field of regenerative medicine, GWOXI Stem Cell is entering the pet regenerative medicine market. Using its multiple patented technologies and extensive clinical experience as a cornerstone, the company is closely addressing the clinical needs of veterinarians and pets, providing a new approach to pet health management.
Expanding the Pet Regenerative Medicine Network
Applying the high standards and facilities used for human clinical preparations, GWOXI Stem Cell adheres to strict quality control to ensure the safety and stability of its products. The company has already partnered with multiple veterinary clinics, veterinary associations, and distributors to establish a pet regenerative medicine network and continues to expand its presence. This strategy not only builds trust in regenerative medicine among veterinarians but also aims to allow more pet owners and their pets to benefit from the innovative results of regenerative medicine technology.
The demand for exosome products is growing rapidly.
According to a report by Grand View Research, the global veterinary regenerative medicine market was valued at $257.54 million in 2022. It is projected to grow rapidly with a high Compound Annual Growth Rate (CAGR) of 12.54% from 2023 to 2030.
With the increasing demand for pet medical care and the accumulation of clinical evidence, regenerative medicine applications are spanning a wide range of diseases. Exosomes, in particular, have attracted significant attention due to their safety, therapeutic potential, and biocompatibility. As per capita income rises and pet owners' acceptance of high-end medical care increases, the application potential of exosomes is being rapidly unleashed. This trend not only presents new market opportunities for businesses but also provides a broader space for technological innovation.
GWOXI's Commitment to Pet Healthcare
GWOXI Stem Cell General Manager Chiu Chun-fen stated: "With the booming growth of the pet economy, pet health management has entered a new golden era. GWOXI Stem Cell is committed to applying exosome technology to pet regenerative medicine to provide owners with innovative, high-quality healthcare solutions. We will continue to strengthen our technology R&D and market presence to help comprehensively improve the quality of life for pets."
In the future, GWOXI Stem Cell will continue to leverage its strengths in the fields of stem cells and exosomes to drive the upgrade of the global pet healthcare industry and create more possibilities for pet healthcare.
The veterinary clinical forum, "Forum of Asia Animal Practice (FAAP)," will be held from January 17th to 19th. GWOXI Stem Cell, in collaboration with Ting Chong International Co., Ltd., will enter the animal healthcare sector, applying exosome technology to various areas such as hair conditioning, wound healing, and cartilage repair. Together with the Taiwan Society of Regenerative Veterinary Medicine, they will usher in a new era of animal regenerative medicine.